Pfizer Rheumatoid Arthritis Drug Beats Older Treatment in Study

Pfizer Inc. (PFE) said its rheumatoid arthritis treatment tofacitinib, one of the company’s leading experimental drugs, was more effective than an older treatment in a large-scale study.

The drug met its primary end-point in the study and no new side effects were found, Pfizer said today in a statement. Pfizer said on a conference call with analysts today that the Food and Drug Administration may need more time than expected to make a decision on approval of the treatment.

The study, dubbed ORAL start, found that tofacitinib was superior to methotrexate in easing pain and swelling of joints caused by rheumatoid arthritis, according to the statement. Results were from the last of three stages of human tests generally required for FDA approval.

Rheumatoid arthritis is a chronic inflammatory disorder that affects about 1.3 million Americans and 23.7 million people worldwide, the company said in the statement.

Pfizer shares jumped 2 percent to $24.19 at 10:44 a.m. in New York trading.

To contact the reporter responsible for this story: Shannon Pettypiece at

To contact the editor responsible for this story: Reg Gale at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.